Monoclonal Antibody, Human Interleukin 5 Antagonist

Monoclonal antibody interleukin-5 antagonists are a class of targeted biologic therapies that inhibit eosinophil-driven inflammation by binding circulating interleukin-5 and preventing it from interacting with the interleukin-5 receptor complex on the eosinophil surface

By neutralizing this key cytokine, these agents reduce the differentiation, recruitment, activation, and survival of eosinophils

In clinical practice, they are primarily indicated as add-on maintenance treatment for severe asthma with an eosinophilic phenotype

In clinical practice, they are primarily indicated as add-on maintenance treatment for severe asthma with an eosinophilic phenotype Selected agents in the class are also approved for other eosinophil-mediated conditions, including eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps